Pharmacogenomics Market, by Technology (DNA Sequencing, Microarray, Polymerase Chain Reaction, Electrophoresis, Mass Spectrometry, and Other Technologies), by Application (Cardiovascular Diseases, Infectious Diseases, Oncology, Neurological Diseases, Psyc

Pharmacogenomics Market, by Technology (DNA Sequencing, Microarray, Polymerase Chain Reaction, Electrophoresis, Mass Spectrometry, and Other Technologies), by Application (Cardiovascular Diseases, Infectious Diseases, Oncology, Neurological Diseases, Psychiatry, Pain Management and Others), by End User (Hospitals & Clinics, Research Institutions and Academic Institutes, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Pharmacogenomics is a branch of pharmacology that studies the influence of genetic variation on drug response in patients by correlating gene expression or single-nucleotide polymorphisms with drug efficacy or toxicity. It seeks to develop rational methods for optimizing drug therapy in relation to the patient's genotype, in order to achieve maximum efficacy with minimal side effects. Such approaches promise the advent of personalized medicine, in which drugs and drug combinations are optimized for each individual's unique genetic makeup. Pharmacogenomics is the whole genome application of pharmacogenetics, which examines the single gene interactions with drugs.
Market Dynamics
Key players operating in the global pharmacogenomics market are focusing on adoption of growth strategies such as collaborations and product approvals, which are expected to drive the market growth during the forecast period. For instance, in February 2019, the University of Arizona College of Medicine-Phoenix and Banner Health collaborated to prevent life-threatening adverse reactions to medications. The Flinn Foundation is a privately endowed, philanthropic grant-making organization, awarded the Division of Clinical Data Analytics and Decision Support (CDADS) at the University of Arizona College of Medicine - Phoenix US$ 1.5 millionto incorporate pharmacogenomics and clinical decision support into clinician training and medical practice. Moreover, in December 2021, Thermo Fisher Scientific, a U.S-based supplier of scientific instrumentation, reagents and consumables, and software services, announced that U.S. FDA had granted premarket approval to Oncomine Dx Target Test as a companion diagnostic (CDx) to help identify non-small cell lung cancer (NSCLC) patients whose tumors carry epidermal growth factor receptor (EGFR) Exon20-insertion mutations for potential treatment with RYBREVANT targeted therapy.
Key features of the study:
This report provides in-depth analysis of the global pharmacogenomics market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global pharmacogenomics market based on the following parameters – Company Highlights, Products Portfolio, Key Highlights, Financial Performance, Strategies
Key companies covered as a part of this study include Admera Health, Abbott Laboratories, Agilent Technologies, Novartis AG, Dynamic DNA Laboratories, Empire Genomics, LLC., Hoffmann-La Roche Ltd., Illumina, Inc., OneOme, LLC, Myriad Genetics Inc., OPKO Health, Inc. (GeneDx.), Thermo Fisher Scientific, Inc., and AltheaDx
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global pharmacogenomics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global pharmacogenomics market.
Detailed Segmentation:
Global Pharmacogenomics Market, By Technology :
DNA Sequencing
Microarray
Polymerase Chain Reaction
Electrophoresis
Mass Spectrometry
Other Technologies
Global Pharmacogenomics Market, By Application :
Cardiovascular Diseases
Infectious Diseases
Oncology
Neurological Diseases
Psychiatry
Pain Management
Others
Global Pharmacogenomics Market, By End User :
Hospitals & Clinics
Research Institutions and Academic Institutes
Others
Global Pharmacogenomics Market, By Region:
North America
By Country
U.S.
Canada
Latin America
By Country
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Country
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Country
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Country
GCC
Israel
Rest of Middle East
Africa
By Country/Sub-region
South Africa
Central Africa
North Africa
Company Profiles
Admera Health.*
Company Highlights
Products Portfolio
Key Highlights
Financial Performance
Strategies
Abbott Laboratories
Agilent Technologies
Novartis AG
Dynamic DNA Laboratories
Empire Genomics, LLC
F. Hoffmann-La Roche Ltd
Illumina, Inc
OneOme, LLC
Myriad Genetics Inc
OPKO Health, Inc. (GeneDx.)
Thermo Fisher Scientific, Inc
AltheaDx
“*” marked represents similar segmentation in other categories in the respective section.